These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28248311)

  • 1. Sansanmycin natural product analogues as potent and selective anti-mycobacterials that inhibit lipid I biosynthesis.
    Tran AT; Watson EE; Pujari V; Conroy T; Dowman LJ; Giltrap AM; Pang A; Wong WR; Linington RG; Mahapatra S; Saunders J; Charman SA; West NP; Bugg TD; Tod J; Dowson CG; Roper DI; Crick DC; Britton WJ; Payne RJ
    Nat Commun; 2017 Mar; 8():14414. PubMed ID: 28248311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic Sansanmycin Analogues as Potent
    Tran W; Kusay AS; Hawkins PME; Cheung CY; Nagalingam G; Pujari V; Ford DJ; Stoye A; Ochoa JL; Audette RE; Hortle E; Oehlers SH; Charman SA; Linington RG; Rubin EJ; Dowson CG; Roper DI; Crick DC; Balle T; Cook GM; Britton WJ; Payne RJ
    J Med Chem; 2021 Dec; 64(23):17326-17345. PubMed ID: 34845906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and in vitro antitubercular evaluation of novel sansanmycin derivatives.
    Li YB; Xie YY; Du NN; Lu Y; Xu HZ; Wang B; Yu Y; Liu YX; Song DQ; Chen RX
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6804-7. PubMed ID: 21982497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NRPS substrate promiscuity leads to more potent antitubercular sansanmycin analogues.
    Xie Y; Cai Q; Ren H; Wang L; Xu H; Hong B; Wu L; Chen R
    J Nat Prod; 2014 Jul; 77(7):1744-8. PubMed ID: 24964393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rescrutiny of the sansanmycin biosynthetic gene cluster leads to the discovery of a novel sansanmycin analogue with more potency against Mycobacterium tuberculosis.
    Shi Y; Wang X; He N; Xie Y; Hong B
    J Antibiot (Tokyo); 2019 Oct; 72(10):769-774. PubMed ID: 31341273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving the N-terminal diversity of sansanmycin through mutasynthesis.
    Shi Y; Jiang Z; Lei X; Zhang N; Cai Q; Li Q; Wang L; Si S; Xie Y; Hong B
    Microb Cell Fact; 2016 May; 15():77. PubMed ID: 27154005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosynthesis of a water-soluble lipid I analogue and a convenient assay for translocase I.
    Siricilla S; Mitachi K; Skorupinska-Tudek K; Swiezewska E; Kurosu M
    Anal Biochem; 2014 Sep; 461():36-45. PubMed ID: 24939461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caprazamycins: Promising lead structures acting on a novel antibacterial target MraY.
    Patel B; Ryan P; Makwana V; Zunk M; Rudrawar S; Grant G
    Eur J Med Chem; 2019 Jun; 171():462-474. PubMed ID: 30933853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Merging Natural Products: Muraymycin-Sansanmycin Hybrid Structures as Novel Scaffolds for Potential Antibacterial Agents.
    Niro G; Weck SC; Ducho C
    Chemistry; 2020 Dec; 26(70):16875-16887. PubMed ID: 32897546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A model to predict anti-tuberculosis activity: value proposition for marine microorganisms.
    Liu M; Grkovic T; Zhang L; Liu X; Quinn RJ
    J Antibiot (Tokyo); 2016 Aug; 69(8):594-9. PubMed ID: 27406906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting natural product value, an exploration of anti-TB drug space.
    Dashti Y; Grkovic T; Quinn RJ
    Nat Prod Rep; 2014 Aug; 31(8):990-8. PubMed ID: 24881816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new nucleosidyl-peptide antibiotic, sansanmycin.
    Xie Y; Chen R; Si S; Sun C; Xu H
    J Antibiot (Tokyo); 2007 Feb; 60(2):158-61. PubMed ID: 17420567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural products as leads for tuberculosis drug development.
    Salomon CE; Schmidt LE
    Curr Top Med Chem; 2012; 12(7):735-65. PubMed ID: 22283816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based manual screening and automatic networking for systematically exploring sansanmycin analogues using high performance liquid chromatography tandem mass spectroscopy.
    Jiang ZB; Ren WC; Shi YY; Li XX; Lei X; Fan JH; Zhang C; Gu RJ; Wang LF; Xie YY; Hong B
    J Pharm Biomed Anal; 2018 Sep; 158():94-105. PubMed ID: 29885606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New perspectives on natural products in TB drug research.
    Pauli GF; Case RJ; Inui T; Wang Y; Cho S; Fischer NH; Franzblau SG
    Life Sci; 2005 Dec; 78(5):485-94. PubMed ID: 16243360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitubercular Marine Natural Products.
    Wang L; Wang J; Liu J; Liu Y
    Curr Med Chem; 2018; 25(20):2304-2328. PubMed ID: 28088903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Precursor-directed biosynthesis of new sansanmycin analogs bearing para-substituted-phenylalanines with high yields.
    Zhang N; Liu L; Shan G; Cai Q; Lei X; Hong B; Wu L; Xie Y; Chen R
    J Antibiot (Tokyo); 2016 Oct; 69(10):765-768. PubMed ID: 26905760
    [No Abstract]   [Full Text] [Related]  

  • 18. Mycobacterium tuberculosis-Secreted Tyrosine Phosphatases as Targets Against Tuberculosis: Exploring Natural Sources in Searching for New Drugs.
    Mascarello A; Chiaradia-Delatorre LD; Mori M; Terenzi H; Botta B
    Curr Pharm Des; 2016; 22(12):1561-9. PubMed ID: 26759082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives on tuberculosis pathogenesis and discovery of anti- tubercular drugs.
    Ntie-Kang F; Yong JN; Owono Owono LC; Sippl W; Megnassan E
    Curr Med Chem; 2014; 21(30):3466-77. PubMed ID: 25005178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.